<DOC>
	<DOC>NCT00213993</DOC>
	<brief_summary>The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.</brief_summary>
	<brief_title>Topical Antiperspirant for Hand-Foot Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<criteria>Has not previously received a regimen that includes 5fluorouracil &gt; 18 years old No known allergy or intolerance to Ban Unscented RollOn Antiperspirant &lt; 18 years of age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>